According to a recent Cytiva news release, 440 cell-based and cell therapy clinical trials were ongoing in 2020. As cell therapies are approved by regulatory bodies around the world, there is a pressing and immediate need to industrialise and automate the workflow.
By automating manual portions of the cell therapy manufacturing workflow, the combined team hope to facilitate the flexibility and speed required to accelerate the manufacture of next generation therapeutics.
“Cell therapies have the potential to transform global healthcare, but their true potential will not be realized until the manufacturing workflow is fully automated. Our collaboration with Multiply Labs will enable us to develop a system that will advance and accelerate the commercial manufacturing of these novel therapeutics to help get them to the patients who need them most,” explained Catarina Flyborg, Vice President of Cytiva.
You may also be interested in:
- [REPORT] The ROI of Automation in Cell-Based Therapy Bioprocessing and Supply Chains
- [ROUNDTABLE] Automating Raw Materials Processes in Cell and Gene Therapy Manufacturing
- [INTERVIEW] Embedding Flexibility into Automated Bioprocessing
The collaboration will incorporate Cytiva’s industry expertise with Multiply Labs’ automation and robotics experience to develop a proof of concept for a robotic system. The approach is reportedly the first-of-its-kind, featuring a cloud-controlled manufacturing system that consists of multiple modules organized around a shared transfer system.
Fred Parietti, Co-founder and CEO of Multiply Labs, added:
The team claims a robotic system of this nature will enable an increased output as well as greater flexibility and easier GMP qualification.
“Advanced robotics has been successfully applied to numerous high-value, high-scale manufacturing processes, from automotives to semiconductors. Combining Cytiva’s process expertise and market-leading technology with our robotics hardware and software expertise has the potential to radically accelerate the development and adoption of these life-saving drugs.”
Source: Cytiva press release
If you enjoyed this news story, you might also be interested to learn more about our upcoming Phacilitate Automation SIG, with a working group dedicated to ‘Automating release for autologous products’.
Find out more about the working group and apply to join, below.